Mads H. Haugen

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

Journal: Breast cancer research : BCR

Published: March 23, 2025

Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer.

Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer.

Journal: Nature communications

Published: November 22, 2024

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Journal: British journal of cancer

Published: May 10, 2024

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

Journal: Molecular oncology

Published: July 11, 2023

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.

Journal: Cancer research communications

Published: July 26, 2022

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Journal: PloS one

Published: July 04, 2022

Liver X receptors induce antiproliferative effects in basal-like breast cancer.

Liver X receptors induce antiproliferative effects in basal-like breast cancer.

Journal: Molecular oncology

Published: June 28, 2022

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.

Journal: Breast cancer (Dove Medical Press)

Published: September 08, 2021

AXL inhibition improves BRAF-targeted treatment in melanoma.

AXL inhibition improves BRAF-targeted treatment in melanoma.

Journal: Scientific reports

Published: July 29, 2021

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.

Journal: Scientific reports

Published: January 22, 2021

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients.

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients.

Journal: Frontiers in oncology

Published: August 02, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026